Covid-19 roundup: De­sert­ed by Roche and plagued by set­backs, Atea march­es on; Eu­rope lines up or­der for Mod­er­na's Omi­cron boost­er

De­spite ini­tial flops, Jean-Pierre Som­ma­dos­si be­lieves his an­tivi­ral biotech still has a role to play in what he sees as a long fight against Covid-19.

“COVID-19 con­tin­ues to be a glob­al emer­gency with wan­ing ef­fi­ca­cy from vac­cines, ther­a­peu­tics and pri­or in­fec­tions dri­ving an un­met med­ical need. New an­tivi­rals with im­proved pro­files are ur­gent­ly need­ed,” Som­ma­dos­si, the CEO of Atea Phar­ma­ceu­ti­cals, said in a quar­ter­ly up­date.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER